Eisai (OTCMKTS:ESALY) Stock Price Down 2.1% – Time to Sell?

Shares of Eisai Co., Ltd. (OTCMKTS:ESALYGet Free Report) dropped 2.1% during mid-day trading on Monday . The company traded as low as $61.00 and last traded at $61.51. Approximately 331,800 shares changed hands during trading, an increase of 445% from the average daily volume of 60,916 shares. The stock had previously closed at $62.8350.

Eisai Stock Down 2.1%

The stock has a fifty day moving average price of $61.51 and a 200 day moving average price of $61.51. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.20 and a quick ratio of 1.77. The stock has a market capitalization of $17.64 billion, a P/E ratio of 70.70, a price-to-earnings-growth ratio of 2.46 and a beta of 0.31.

Eisai Company Profile

(Get Free Report)

Eisai Co, Ltd. is a research-driven global pharmaceutical company headquartered in Tokyo, Japan. Founded in 1941 by Toyoji Naito, Eisai focuses on the discovery, development, manufacture and commercialization of prescription medicines and related healthcare products. The company emphasizes neuroscience and oncology as core therapeutic areas and invests in both small-molecule and biologic research to address unmet medical needs.

Among its well-known products, Eisai developed and markets Aricept (donepezil), a widely used treatment for the symptoms of Alzheimer’s disease, and LENVIMA (lenvatinib), an oncology therapy for several tumor types.

See Also

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.